ストックスクリーナーアプリを入手
1.73
4.42%
-0.08
アフターアワーズ：
1.70
-0.03
-1.73%
前日終値:
$1.81
開ける：
$1.75
24時間の取引高:
23,381
Relative Volume:
0.21
時価総額：
$14.91M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.42%
1か月 パフォーマンス:
-25.43%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.73
$1.81
1週間の範囲:
$1.70
$1.866
52週間の値動き範囲:
$1.51
$2.75
Metavia Inc Stock (MTVA) Company Profile
MTVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.73 | 14.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
Metavia Inc (MTVA) 最新ニュース
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NeuroBo Pharmaceuticals : Statement of Changes in Beneficial OwnershipForm 4 -July 28, 2022 at 09:34 pm EDT - Marketscreener.com
2024 Initations - Zacks Small Cap Research
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025 - MSN
Biotech Advances Breakthrough Cancer Treatment Results - Streetwise Reports
MetaVia Advances Therapeutics with Promising Trial Updates - TipRanks
Walgreens tops Wall Street's expectations as drugstore chain continues turnaround plan - 69News WFMZ-TV
Greece bans windowless basements, freezes central Athens licenses in overhaul of short-term rentals - 69News WFMZ-TV
US added a strong 256,000 jobs in December as unemployment rate dipped to 4.1% - 69News WFMZ-TV
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - The Herald Journal
Childhood Smoking Ups COPD Risk - 69News WFMZ-TV
Advisory firm recommends changes at Air Products - 69News WFMZ-TV
Can Doctors Estimate Life Expectancy After a Dementia Diagnosis? - 69News WFMZ-TV
Stock market today: World shares slide further as rate cut, tariff worries hit market sentiment - 69News WFMZ-TV
Tanker hit by Houthi rebels that threatened a Red Sea oil spill has been salvaged - 69News WFMZ-TV
How the wildfires in the Los Angeles area could affect California's home insurance market - 69News WFMZ-TV
Meloni says Italy is exploring deals on telecoms security, but denies private talks with Musk - 69News WFMZ-TV
Revenue Surge & Breakthrough Margins Fuel Growth in Critical Care Tech - Streetwise Reports
Nearly half of Americans carry spare underwear for emergencies - 69News WFMZ-TV
‘Mufasa’ and ‘Sonic 3’ rule first weekend of 2025 - 69News WFMZ-TV
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
What is HC Wainwright’s Estimate for MetaVia Q4 Earnings? - Defense World
Analysts Offer Predictions for MetaVia FY2024 Earnings - Defense World
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
MetaVia (NASDAQ:MTVA) Now Covered by Analysts at HC Wainwright - Defense World
MetaVia shares debut with Buy rating as DA-1726 shows preclinical weight-loss results - Investing.com Nigeria
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
American consumers feeling less confident in December, Conference Board says - 69News WFMZ-TV
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… - Zacks Small Cap Research
MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH - PR Newswire
MTVA stock touches 52-week low at $2 amid market challenges - Investing.com Australia
Clinical Trials News Live Feed - StockTitan
Artificial Intelligence (AI) News Live Feed - StockTitan
MetaVia Reports Positive Phase 2a Clinical Trial Results - TipRanks
MetaVia reports positive DA-1241 trial results for MASH - Investing.com
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH - The Eastern Progress Online
NeuroBo Pharmaceuticals : Reports Third Quarter 2021 Financial ResultsForm 8-K - Marketscreener.com
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
MTVA stock touches 52-week low at $2.04 amid market challenges - Investing.com Canada
MTVA stock touches 52-week low at $2.04 amid market challenges By Investing.com - Investing.com South Africa
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now - The Manila Times
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now - GlobeNewswire
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
Metavia Inc (MTVA) 財務データ
Metavia Inc (MTVA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):